Outcomes Following Combined Adductoplasty™ and Lapiplasty® (MTA3D)

Description

Prospective, multicenter, unblinded study to evaluate outcomes of the Adductoplasty™ Procedure in combination with the Lapiplasty® Procedure for patients in need of metatarsus adductus and hallux valgus correction. Up to 80 subjects will be treated in this study at up to 13 clinical sites. Patients 14 years of age or older with symptomatic metatarsus adductus and hallux valgus will be eligible to participate based on the inclusion and exclusion criteria defined in the study protocol.

Conditions

Metatarsus Adductus, Hallux Valgus

Study Overview

Study Details

Study overview

Prospective, multicenter, unblinded study to evaluate outcomes of the Adductoplasty™ Procedure in combination with the Lapiplasty® Procedure for patients in need of metatarsus adductus and hallux valgus correction. Up to 80 subjects will be treated in this study at up to 13 clinical sites. Patients 14 years of age or older with symptomatic metatarsus adductus and hallux valgus will be eligible to participate based on the inclusion and exclusion criteria defined in the study protocol.

Radiographic and Patient Reported Outcomes Following Combined Adductoplasty™ and Lapiplasty® Procedures for Correction of Metatarsus Adductus and Hallux Valgus (MTA3D)

Outcomes Following Combined Adductoplasty™ and Lapiplasty® (MTA3D)

Condition
Metatarsus Adductus
Intervention / Treatment

-

Contacts and Locations

Greeley

Foot and Ankle Center of the Rockies, Greeley, Colorado, United States, 80634

Ankeny

Foot and Ankle Center of Iowa, Ankeny, Iowa, United States, 50023

Yarmouth

Coastal Maine Foot and Ankle, Yarmouth, Maine, United States, 04096

Jefferson City

JCMG - Jefferson City Medical Group, Jefferson City, Missouri, United States, 65019

Morrisville

Duke Orthopaedics Arringdon, Morrisville, North Carolina, United States, 27560

Canton

Ohio Foot and Ankle Center, Canton, Ohio, United States, 44708

Stow

Ohio Foot and Ankle Center, Stow, Ohio, United States, 44224

Wexford

Greater Pittsburgh Foot and Ankle Center, Wexford, Pennsylvania, United States, 15090

Keller

Foot and Ankle Associates of North Texas - Keller, Keller, Texas, United States, 76248

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Male and females ≥14 years old at the time of consent
  • 2. Closed physeal plates at the time of consent
  • 3. Intermetatarsal angle is ≥8.0˚; OR True IMA of \>10°, (IMA+MTA-15=True IMA)
  • 4. Hallux valgus angle is ≥12.0˚
  • 5. Metatarsus adductus angle based on Sgarlatos method ≥15°
  • 6. Willing and able to adhere to post-op care instructions
  • 7. Capable of completing self-administered questionnaires
  • 8. Acceptable surgical candidate, including use of general anesthesia
  • 9. Female patients must be of non-childbearing potential or have a negative pregnancy test in accordance with hospital standards prior to the Index Procedure
  • 10. Willing and able to schedule index procedure within 3 months of consent and able to return for scheduled follow-up visits
  • 11. Willing and able to provide written informed consent
  • 12. Patient agrees to refrain from any reconstructive procedures on contralateral foot for minimum of 6 months post index procedure
  • 1. Previous surgery for hallux valgus on operative side
  • 2. Previous surgeries on operative foot involving fusion of foot or ankle joints (other than hammertoe, lesser toes/digits, or posterior muscle lengthening)
  • 3. Moderate-severe osteoarthritis of the foot or ankle outside of the 1st, 2nd or 3rd tarsometatarsal joints
  • 4. Moderate-severe osteoarthritis of the 1st, 2nd or 3rd tarsometatarsal joints
  • 5. Any deformity of the hindfoot or midfoot that represents a pathological condition that may affect the outcome of the tarsometatarsal realignment, or a condition that requires concomitant surgical correction
  • 6. BMI \>40 kg/m²
  • 7. Current nicotine user in any form including vaping, smoking, oral ingestion or use of nicotine patch
  • 8. Current clinical diagnosis of diabetes or currently taking medication for treatment of diabetes
  • 9. Current clinical diagnosis of peripheral neuropathy
  • 10. Current clinical diagnosis of fibromyalgia
  • 11. Current clinical diagnosis of Complex Regional Pain Syndrome/Reflex Sympathetic Dystrophy (CRPS/RSD)
  • 12. Current uncontrolled hypothyroidism
  • 13. Current clinical diagnosis of chronic dependent edema
  • 14. Previously sensitized to titanium
  • 15. Currently taking oral steroids or rheumatoid biologics
  • 16. Currently taking immunosuppressant drugs
  • 17. Insufficient quantity or quality of bone to permit stabilization, conditions that inhibit healing (not including pathological fractures) and conditions causing poor blood supply such as peripheral vascular disease
  • 18. Active, suspected, or latent infection in the affected area
  • 19. Use of synthetic or allogenic bone graft substitutes
  • 20. Use of non-Treace products for Index Procedure
  • 21. Additional bone procedure needed during the index procedure to complete correction (additional metatarsal or tarsal bone osteotomy or fusion, first MTP fusion, calcaneal osteotomy, traditional medial eminence resection);
  • 22. Scheduled to undergo a same-day bilateral procedure
  • 23. Patient has previously been enrolled into this study for a contralateral procedure
  • 24. Scheduled for any concomitant procedure that would alter patient's ability to weight-bear post-procedure
  • 25. Patient is actively involved with a workman's compensation case or is currently involved in litigation
  • 26. Patient is currently in, or has participated in, a clinical study in the last 30 days prior to signing informed consent or is considering participation in another research protocol during this study. Exceptions to this include survey clinical studies with no treatment or if subject is greater than 12 months post procedure in either the Treace ALIGN3D™ or Mini3D™ Study without ongoing protocol defined AE
  • 27. Patient has a condition or finding that, in the opinion of the Investigator, may jeopardize the patient's well-being, the soundness of this clinical study, or could interfere with provision of informed consent, completion of tests, therapy, or follow-up

Ages Eligible for Study

14 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Treace Medical Concepts, Inc.,

Paul Dayton, DPM, PRINCIPAL_INVESTIGATOR, Foot and Ankle Center of Iowa

Mark Easley, MD, PRINCIPAL_INVESTIGATOR, Duke University

Study Record Dates

2029-12-31